Bibliografía del artículo
1. PAHO-WHO 2006. Estimación cuantitativa de la enfermedad de Chagas en las Américas. OPS/HDM/CD/425-06, 2006.
2. Hagar JM, Rahimtoola SH. Chagas' heart disease. Curr Probl Cardiol 20:825-924, 1995.
3. Rassi A Jr, Rassi SG, Little WC. Chagas' heart disease. Clin Cardiol 23:883-889, 2000.
4. Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz 94:317-320, 1999.
5. Rassi A Jr, Rassi SG. Sudden death in Chagas disease. Arq Bras Cardiol 76:75-96, 2001.
6. Engman D, Leon J. Pathogenesis of Chagas heart disease: role of autoimnunity. Acta Trop 81:123-132, 2002.
7. Cunha-Neto E, Bilate A, Hyland K, Fonseca S, Kalil J, Engman D. Induction of cardiac autoimmunity in Chagas heart disease: A case for molecular mimicry. Autoimmunity 39:41-54, 2006.
8. Laguens R, Cabeza Meckert P, Vigliano C. Patogenia de la miocarditis chagásica crónica humana. Medicina (Bs. As.) 59:63-68, 1999.
9. Rodrigues Coura J, Castro SL. A critical review on Chagas disease chemotheraphy. Mem Inst Oswaldo Cruz 97:3-24, 2002.
10. Tarleton RL, Zhang L. Chagas Disease Etiology. Autoimmunity or parasite persistence? Parasitol Today 15:94-99, 1999.
11. Bellotti G, Bocchi EA, Moraes AV. In vivo detection of Trypanosoma cruzi antigens in hearts of patiens with chronic Chagas' heart disease. Am Heart J 131:301-307, 1996.
12. Brandariz S, Schijman A, Vigliano C, Viotti R, Levin MJ. Role of parasites in the pathogenesis of Chagas' cardiomyopathy. Lancet 347:914, 1996.
13. Kierszenbaum F. Mechanisms of pathogenesis in Chagas disease. Acta Parasitol 52:1-12, 2007.
14. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 8:510-518, 2008.
15. Rassi A Jr, Rassi A, Marin-Neto J. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 104:152-158, 2009.
16. Castro J, Toranzo ED. Toxic effects of nifurtimox and benznidazole. Two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1:19-33, 1988.
17. Stoppani A. Quimioterapia de la enfermedad de Chagas. Medicina (Bs. As.) 59:147-165, 1999.
18. Filardi LS, Brener Z. Susceptibity and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 81:755-759, 1987.
19. Campos RF, Guerreiro ML, Sobral K, Lima R, Andrade SG. Response to chemotherapy with benznidazole of clones isolates from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II). Rev Soc Bras Med Trop 38:142-146, 2005.
20. Andrade ALS, Zicker F, Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413, 1996.
21. Barclay CA, Cerisola JA, Lugones H, Ledesma O, Silva L, Bouzo G. Aspectos farmacológicos y resultados terapéuticos del benznidazol en el tratamiento de la infección chagásica. Prensa Med Argent 65:239-244, 1978.
22. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop São Paulo 44:1-21, 2002.
23. Cerisola JA. Chemotherapy of Chagas infections in man. Scientific Publication Pan Am Health Org N° 347, 1977.
24. Estani SS, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemoterapy with benznidazole in children in the indeterminate phase of Chagas'disease. Am J Trop Med Hyg 59:526-529, 1998.
25. Fabbro D, Arias E, Streiger M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop São Paulo 42:99-109, 2000.
26. Fabbro D, Streiger M, Arias E, Bizai M, Del Barco M, Amicone N. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina) over a mean follow-up of 21 years: pasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40:1-10, 2007.
27. Ferreira HO. Tratamento da forma indeterminada da doença de Chagas com nifurtimox e benznidazol. Rev Soc Bras Med Trop 23:209-211, 1990.
28. Fernandes CD, Tiecher FM, Balbinot MM, et al. Efficacy of benznidazole treatment for asymptomatic chagasic patients state of Rio Grande do Sul evaluated during a three years follow-up. Men Inst Oswaldo Cruz 104:27-32, 2009.
29. Moya P, Paollaso R, Blanco S, et al. Tratamiento de la enfermedad de Chagas con Nifurtimox durante los primeros meses de vida. Medicina (Bs. As.) 45:553-558, 1985.
30. Streiger M, Fabbro D, Del Barco M, Beltramino R, Bovero N. Chagas congénito en la ciudad de Santa Fe: diagnóstico y tratamiento. Medicina (Bs As) 55:125-133, 1995.
31. Streiger ML, Del Barco ML, Fabbro DL, Arias ED, Amicone NA. Estudo longitudinal e quimioterapia específica em crianças, com doença de Chagas crônica, residentes em área de baixa endemicidade da República Argentina. Rev Soc Bras Med Trop 37:365-375, 2004.
32. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long term follow-up. Am Heart J 127:151-162, 1994.
33. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Inter Med 144:724-734, 2006.
34. Cançado JR. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 94:331-335, 1999.
35. Ministerio de Salud y Ambiente de la Nación. Guía para la atención del paciente infectado con Trypanosoma cruzi. Resolución 1870/2006 www.msal.gov.ar.
36. Cançado JR. Terapêutica específica. En Dias JCP, Coura, JR. Clínica e terapêutica da doença de Chagas. Río de Janeiro, Ed Fiocruz, pp. 323-351, 1997.
37. Cançado JR. Tratamento etiológico da doença de Chagas pelo benznidazole. In Brener Z, Andrade ZA, Barral-Netto M. Trypanosoma cruzi e doença de Chagas. 2a ed Río de Janeiro, Guanabara Koogan, p. 389, 2000.
38. Hyland K, Leon J, Daniels M, et al. Modulation of autoimmunity by treatment of an infectious disease. Inf Immun 75:3641-3650, 2007.
39. Garcia S, Ramos C, Senra J, et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 49:1541-1528, 2005.